Ads
related to: monoclonal antibodiescreative-biolabs.com has been visited by 100K+ users in the past month
Search results
KeyBanc maintains overweight rating on ABCL stock By Investing.com
Investing.com· 5 days agoOn Thursday, KeyBanc Capital Markets reaffirmed its positive stance on AbCellera Biologics...
Molecular fingerprinting of biological nanoparticles with a label-free optofluidic platform - Nature...
Nature· 6 days agoIn this work, we fulfilled the requirements for label-free molecular fingerprinting of heterogeneous nanoparticle suspensions by focussing our efforts around three main concepts: (i) large FOV ...
Q1 2024 Voyager Therapeutics Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 7 days agoAs Al mentioned, we're excited to announce that VY-TAU01, our anti-tau monoclonal antibody, obtained IND clearance. And we look forward to announcing, in ...
Eisai projects Leqembi® revenue to total JPY 56.5 billion for fiscal year 2024 (April 2024 - March...
FOX 4 Kansas City· 6 days agoBioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today said that they expect Leqembi...
BioInvent to Present Additional Promising Phase 1/2a Data at EHA 2024 for BI-1206 with rituximab in...
Digital Journal· 6 days agoFirst data for the SC arm: 1 complete response (CR), 2 partial response (PR), 1 stable disease (SD) out of 4 evaluable patients.Further updates from the IV arm; a fifth CR has been observed, ...
Immunovant, Inc. (NASDAQ:IMVT) Short Interest Update
ETF DAILY NEWS· 4 days agoImmunovant, Inc. (NASDAQ:IMVT – Get Free Report) was the recipient of a significant growth in short interest in April. As of April 30th, there was short interest totalling 8,960,000 shares, ...
HC Wainwright Cuts Cullinan Oncology (NASDAQ:CGEM) Price Target to $28.00
ETF DAILY NEWS· 2 days agoCullinan Oncology (NASDAQ:CGEM – Free Report) had its target price decreased by HC Wainwright from $29.00 to $28.00 in a report released on Thursday morning, Benzinga reports. HC Wainwright ...
BioMarin sheds 170 jobs in wake of narrowed R&D refocus
FierceBiotech· 6 days agoBioMarin had already announced plans to cut its pipeline in half, but now the company has confirmed...
HaemaLogiX welcomes former Australian Federal Minister for Health Professor the Hon Greg Hunt to the...
WPRI Providence· 19 hours agoHaemaLogiX Ltd, a clinical stage biotech developing novel immunotherapies for patients with blood cancers and B-cell diseases, is pleased to announce the appointment of Professor the Hon Greg ...
Annexon, Inc. (NASDAQ:ANNX) Receives $14.14 Average Price Target from Analysts
ETF DAILY NEWS· 1 day agoShares of Annexon, Inc. (NASDAQ:ANNX – Get Free Report) have earned an average recommendation of “Buy” from the six research firms that are presently covering the stock, MarketBeat reports.